Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 38832972

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2024 Oct 31
First author
Facon T

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2025 Jan 30;392(5):518-519. doi: 10.1056/NEJMc2414957.
    note
    Source null
    related pmid
    39879604
    relationship
    Comment in
  2. citation
    N Engl J Med. 2025 Jan 30;392(5):519-520. doi: 10.1056/NEJMc2414957.
    note
    Source null
    related pmid
    39879605
    relationship
    Comment in

Authors and identifiers

  1. name
    Facon T
    type
    Author
  2. name
    Dimopoulos MA
    type
    Author
  3. name
    Leleu XP
    type
    Author
  4. name
    Beksac M
    type
    Author
  5. name
    Pour L
    type
    Author
  6. name
    Hájek R
    type
    Author
  7. name
    Liu Z
    type
    Author
  8. name
    Minarik J
    type
    Author
  9. name
    Moreau P
    type
    Author
  10. name
    Romejko-Jarosinska J
    type
    Author
  11. name
    Spicka I
    type
    Author
  12. name
    Vorobyev VI
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Facon T
    type
    Author
  2. name
    Dimopoulos MA
    type
    Author
  3. name
    Leleu XP
    type
    Author
  4. name
    Beksac M
    type
    Author
  5. name
    Pour L
    type
    Author
  6. name
    Hájek R
    type
    Author
  7. name
    Liu Z
    type
    Author
  8. name
    Minarik J
    type
    Author
  9. name
    Moreau P
    type
    Author
  10. name
    Romejko-Jarosinska J
    type
    Author
  11. name
    Spicka I
    type
    Author
  12. name
    Vorobyev VI
    type
    Author
bibliography ids
  1. nci-bib-e948c641e857ddb7bd4db64d
book metadata
content sha256
6bcd40caa15c8731474771be1615894b8603e22483e5e4bb162f77a14bd815c7
document type
citation
dois
  1. 10.1056/NEJMoa2400712
electronic publication date
display
2024 Jun 3
precision
day
year
2024
evidence scope
bibliographic_metadata_only
id
pubmed:38832972
immutable id
pubmed:38832972@6bcd40caa15c8731474771be1615894b8603e22483e5e4bb162f77a14bd815c7
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
17
name
The New England journal of medicine
nlm unique id
0255562
pages
1597-1609
volume
391
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2025 Jan 30;392(5):518-519. doi: 10.1056/NEJMc2414957.
    note
    Source null
    related pmid
    39879604
    relationship
    Comment in
  2. citation
    N Engl J Med. 2025 Jan 30;392(5):519-520. doi: 10.1056/NEJMc2414957.
    note
    Source null
    related pmid
    39879605
    relationship
    Comment in
outcomes validated
false
pmid
38832972
provenance
batch id
3e43afde6f26fc8df6da
provider
NCBI PubMed ESummary
record sha256
1443c77df711f026b934836a33540437b4e95c41c7fe52ff53c28a1f3f0738f0
response sha256
fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
retrieved at
2026-09-09T23:48:21.145285+00:00
publication date
display
2024 Oct 31
precision
day
year
2024
publication types
  1. Journal Article
  2. Randomized Controlled Trial
  3. Clinical Trial, Phase III
  4. Multicenter Study
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/38832972/
title
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Preserved source evidence · Not medical advice